Clinigen Group plc announced it has signed an exclusive partnership agreement with PAION for the supply and distribution of key products into the UK. The first product within the agreement will be Byfavo (remimazolam) which has been approved by the European Commission in the EU in March 2021 and by the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK in June 2021. Byfavo is the first product developed by PAION to be approved and launched in Europe.

In addition, PAION has two further products, GIAPREZA (angiotensin II) and XERAVA (eravacycline), in its portfolio that have also been launched recently outside the UK. Under the terms of the agreement Clinigen will manage the supply and distribution of PAION's licensed products in the UK.